Acta Vet. Brno 2022, 91: 217-226

In field review of Bovalto® Respi 3 and 4 efficacy in different production systems

Matthew Yarnall1, Edmond Jolivet2, Mathieu Chevalier2, Arnaud Bolon2, Marie-Pascale Tiberghien3, Milan Huňady4, Corinne Philippe2

1Boehringer Ingelheim Vetmedica GmbH, Ingelheim, Germany
2Boehringer Ingelheim, Lyon, France
3Consulting, Cortambert, France
4Bioveta, Ivanovice na Hané, Czech Republic

Received November 17, 2021
Accepted June 14, 2022

Three field studies (Phase 4, immediate efficacy) were conducted with an inactivated, adjuvanted, tri or quadri-valent respiratory vaccine for cattle (bovine respiratory syncytial virus [BRSV], parainfluenza 3 virus [Pi3V], Mannheimia haemolytica ± bovine viral diarrhoea virus [BVDV]), compared to competitor vaccines, in three different production systems: allotted fattening bulls, beef calves on their farm of birth, allotted veal calves. Mortality, morbidity, pre and post-vaccinal serological data (ELISA and virus neutralising titres) were compared between groups. There were no significant differences in mortality and morbidity between the groups. In the fattening bulls study, significantly fewer bovine respiratory disease treatments were administered to animals in the Bovalto group. Virus neutralising titre results were not different between groups, except for BVDV in Study 3 where a BVDV outbreak was observed.


All three studies were financed by Boehringer Ingelheim and all authors are in a direct or indirect (MPT) employment of Boehringer Ingelheim.


13 live references